Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.67 |
| ▸ | HTR1A | P08908 | 15/20 | 0.48 |
| ▸ | DRD2 | P14416 | 15/20 | 0.48 |
| ▸ | HTR2A | P28223 | 15/20 | 0.48 |
| ▸ | DRD3 | P35462 | 12/20 | 0.48 |
| ▸ | CMA1 | P23946 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL222028 | 0.81 | ACHE (1.00) | ACHE | |
| Maleic Acid SCHEMBL6987772 | 0.80 | ACHE (0.84) | ACHE | |
| Fumaric Acid SCHEMBL6987773 | 0.80 | ACHE (0.84) | ACHE | |
| SCHEMBL28814086 | 0.80 | ACHE (0.80) | ACHE | |
| Maleic Acid SCHEMBL27339116 | 0.80 | ACHE (0.69) | ACHEHTR1ADRD2HTR2ADRD3 | |
| Maleic Acid SCHEMBL27339115 | 0.80 | ACHE (0.69) | ACHEHTR1ADRD2HTR2ADRD3 | |
| SCHEMBL1581512 | 0.76 | ACHE (0.67) | ACHEDRD2HTR2ADRD3 | |
| SCHEMBL6989946 | 0.76 | ACHE (0.67) | ACHE | |
| SCHEMBL8670678 | 0.74 | MAOA (0.55) | — | |
| SCHEMBL1581739 | 0.72 | SLC18A2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0646115-B1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | EISAI CO LTD (JP) | 2003-01-22 | — | — | EP | disclosed |
| US-6498255-B2 | CHOLINESTERASE INHIBITORS; COGNITION ACTIVATORS; ALZHEIMER'S DISEASE; E.G., 3-(2-(1-(PHENYLMETHYL)-4-PIPERIDINYL)ETHYL)-1,2-BENZISOXAZOLE | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | VILLALOBOS ANABELLA (US) | 2002-03-07 | — | — | US | disclosed |
| US-6326382-B1 | CHOLINESTERASE INHIBITORS; USEFUL IN ENHANCING MEMORY IN PATIENTS SUFFERING FROM DEMENTIA AND ALZHEIMER'S DISEASE | EISAI CO., LTD (JP) | 2001-12-04 | — | — | US | disclosed |
| CN-1044242-C | Heterocyclic-cyclic amine derivatives | PFIZER (US) | 1999-07-21 | — | — | CN | disclosed |
| US-5538984-A | Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors | PFIZER INC. (US) | 1996-07-23 | — | — | US | disclosed |
| EP-0646115-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1995-04-05 | — | — | EP | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
| CN-1065267-A | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER (US) | 1992-10-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028834-A1 | Heterocyclic-cyclic amine derivatives | BCHE, ACHE, CHRM1 | ACHE 2/4885HTR1A 160/4885DRD2 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.